Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons

Journal of Virology

Volumn 73, Issue 12, 1999, Pages 10426-10439

  Sena Esteves, Miguel ^a   Saeki, Yoshinaga ^a   Camp, Sara M ^a   Chiocca, E Antonio ^a   Breakefield, Xandra O ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; EPSTEIN BARR VIRUS; GENE ACTIVITY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 0032728378     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.12.10426-10439.1999     Document Type: Article

References (70)

1. Aboody, K. S., N. Rainov, J. E. Small, S. Liu, K. A. Bower, U. Herrlinger, P. Black, X. O. Breakefield, and E. Y. Snyder. Neural stem cells migrate throughout and express foreign genes within experimental gliomas: a potential gene therapy approach to brain tumors. Submitted for publication.
2. Bender, M. A., T. D. Palmer, R. E. Gelinas, and A. D. Miller. 1987. Evidence that the packaging signal of Moloney leukemia virus extends into the gag region. J. Virol. 61:1639-1646.
3. Berens, M. E., G. Bjotvedt, D. C. Levesque, M. D. Rief, J. R. Shapiro, and S. W. Coons. 1993. Tumorigenic, invasive, karyotypic, and immunocytochemical characteristics of clonal cell lines derived from a spontaneous canine anaplastic astrocytoma. In Vitro Cell. Dev. Biol. Anim. 29A:310-318.
4. Brown, A. B., E. Marecos, R. Weissleder, and X. O. Breakefield. Vascular targeting of therapeutic cells to tumors. Submitted for publication.
5. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J.-K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90:8033-8037.
6. Chakraborty, A. K., M. A. Zink, and C. P. Hodgson. 1994. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy. Cancer Gene Ther. 1:113-118.
7. Chattopadhyay, S. K., A. I. Oliff, D. L. Linemeyer, M. R. Lander, and D. R. Lowy. 1981. Genomes of murine leukemia viruses isolated from wild mice. J. Virol. 39:777-791.
8. Coffin, J. M. 1996. Retroviridae: the virus and their replication, p. 1767-1848. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology. Raven Publishers, Philadelphia, Pa.
9. Cosset, F.-L., Y. Takeuchi, J.-L. Battini, R. A. Weiss, and M. K. L. Collins. 1995. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69:7430-7436.
10. Culver, K. W., Z. Ram, S. Wallbridge, H. Ishli, E. H. Oldfield, and R. M. Blaese. 1992. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256:1550-1552.
11. Cunningham, C., and A. J. Davison. 1993. A cosmid-based system for constructing mutants of herpes simplex virus type I. Virology 197:116-124.
12. Dranoff, G., E. Jaffe, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539-3543.
13. Duisit, G., A. Salvetti, P. Moullier, and F. L. Cosset. 1999. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum. Gene Ther. 10: 189-200.
14. Fekete, D. M., and C. L. Cepko. 1993. Replication-competent retroviral vectors encoding alkaline phosphatase reveal spatial restriction of viral gene expression/transduction in the chick embryo. Mol. Cell. Biol. 13:2604-2613.
15. Feng, M., J. W. H. Jackson, C. K. Goldman, C. Rancourt, M. Wang, S. K. Dusing, G. Siegal, and D. T. Curiel. 1997. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol. 15:866-870.
16. Fisher, K. J., H. Choi, J. Burda, S.-J. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
17. Fraefel, C., X. O. Breakefield, and D. R. Jacoby. 1998. HSV-1 amplicon, p. 63-82. In E. A. Chiocca and X. O. Breakefield (ed.), Gene therapy for neurological disorders and brain tumors. Humana Press, Inc., Totowa, N.J.
18. Fraefel, C., S. Song, F. Lim, P. Lang, L. Yu, Y. Wang, P. Wild, and A. I. Geller. 1996. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70:7190-7197.
19. Fruh, K., K. Ahn, H. Djaballah, P. Sempe, P. M. van Endert, R. Tampe, P. A. Peterson, and Y. Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415-418.
20. Goldman, M. J., P.-S. Lee, J.-S. Yang, and J. M. Wilson. 1997. Lentiviral vectors for gene therapy of cystic fibrosis. Hum. Gene Ther. 8:2261-2268.
21. Gross, J. L., D. L. Behrens, D. E. Mullins, P. L. Kornblith, and D. L. Dexter. 1988. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res. 48:291-296.
22. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366.
23. Hatzoglou, M., C. P. Hodgson, F. Mularo, and R. W. Hanson. 1990. Efficient packaging of a specific VL30 retroelement by psi 2 cells which produce MoMLV recombinant retroviruses. Hum. Gene Ther. 1:385-397.
24. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell, H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415.
25. Isacson, O., and X. O. Breakefield. 1997. Benefits and risks of hosting animal cells in the human brain. Nat. Med. 3:964-969.
26. Johnston, K. M., D. R. Jacoby, P. A. Pechan, C. Fraefel, P. Borghesani, D. Schuback, R. J. Dunn, F. I. Smith, and X. O. Breakefield. 1997. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 8:359-370.
27. Jolly, D. 1995. Viral vector systems for gene therapy, p. 51-64. In R. E. Sobol and K. J. Scanlon (ed.), The internet book of gene therapy. Cancer therapeutics. Appleton and Lange, Stamford, Conn.
28. Karacostas, V., E. J. Wolffe, K. Nagashima, M. A. Gonda, and B. Moss. 1993. Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661-671.
29. Kasahara, N., A. M. Dozy, and Y. W. Kan. 1994. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 264:1373-1376.
30. Kasid, A., S. Morecki, P. Abersold, K. Cornetta, K. Culver, S. Freeman, E. Director, M. T. Lotze, R. M. Blaese, W. F. Anderson, et al. 1990. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc. Natl. Acad. Sci. USA 87:473-477.
31. Kim, S. H., S. S. Yu, J. S. Park, P. D. Robbins, C. S. An, and S. Kim. 1998. Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol. 72:994-1004.
32. Kochanek, S., P. R. Clemens, K. Mitani, H.-H. Chen, S. Chan, and C. T. Caskey, 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93:5731-5736.
33. Kruse, C. A., M. C. Molleston, E. P. Parks, P. M. Schiltz, B. K. Kleinschmidt-DeMasters, and W. F. Hickey. 1994. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J. Neurooncol. 22:191-200.
34. Kumar-Singh, R., and J. S. Chamberlain. 1996. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5:913-921.
35. Kurre, P., H.-P. Kiem, J. Morris, S. Heyward, J.-L. Battini, and A. D. Miller. 1999. Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor. J. Virol. 73: 495-500.
36. Lal, B., R. R. Indurti, P. O. Couraud, G. W. Goldstein, and J. Laterra. 1994. Endothelial cell implantation and survival within experimental gliomas. Proc. Natl. Acad. Sci. USA 91:9695-9699.
37. Laquerre, S., D. B. Anderson, D. B. Stolz, and J. C. Glorioso. 1998. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. 72:9683-9697.
38. Leigh, M. W., J. E. Kylander, J. R. Yankaskas, and R. C. Boucher. 1995. Cell proliferation in bronchial epithelium and submucosal glands of cystic fibrosis patients. Am. J. Respir. Cell. Mol. Biol. 12:605-612.
39. Li, K.-J., and H. Garoff. 1996. Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors. Proc. Natl. Acad. Sci. USA 93:11658-11663.
40. Lin, X. 1998. Construction of new retroviral producer cells from adenoviral and retroviral vectors. Gene Ther. 5:1251-1258.
41. Mann, R., R. C. Mulligan, and D. Baltimore. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159.
42. Montgomery, R. I., M. S. Warner, B. J. Lum, and P. G. Spear. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/ NGF receptor family. Cell 87:427-436.
43. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
44. Nagane, M., F. Coufal, H. Lin, O. Bogler, W. K. Cavenee, and H.-J. S. Huang. 1996. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:5079-5086.
45. Naviaux, R. K., E. Costanzi, M. Haas, and I. M. Verma. 1996. The pCL system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:5701-5705.
46. Nelson, D. M., M. E. Metzger, R. E. Donahue, and R. A. Morgan. 1997. In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning. Hum. Gene Ther. 8:747-754.
47. Noguiez-Hellin, P., M. Robert-LeMeur, J.-L. Salzmann, and D. Klatzmann. 1996. Plasmoviruses: nonviral/viral vectors for gene therapy. Proc. Natl. Acad. Sci. USA 93:4175-4180.
48. Palombo, F., A. Monciotti, A. Recchia, R. Cortese, G. Ciliberto, and N. LaMonica. 1998. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J. Virol. 72:5025-5034.
49. Patience, C., Y. Takeuchi, F.-L. Cosset, and R. A. Weiss. 1998. Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J. Virol. 72:2671-2676.
50. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
51. Pederson, P.-H., K. Marienhagen, S. Mork, and R. Bjerkvig. 1993. Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res. 53:5158-5165.
52. Puumalainen, A.-M., M. Vapalahti, R. S. Agrawal, M. Kossila, J. Laukkanen, P. Lehtolainen, H. Viita, L. Paljarvi, R. Vanninen, and S. Yla-Herttuala. 1998. β-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9:1769-1774.
53. Ram, Z., K. W. Culver, E. M. Oshiro, J. J. Viola, H. L. DeVroom, E. Otto, Z. Long, Y. Chiang, G. J. McGarrity, L. M. Muul, D. Katz, R. M. Blaese, and E. H. Oldfield. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3:1354-1361.
54. Rother, R. P., W. L. Fodor, J. P. Springhorn, C. W. Birks, E. Setter, M. S. Sandrin, S. P. Squinto, and S. A. Rollins. 1995. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. 182:1345-1355.
55. Saeki, Y. Unpublished data.
56. Savard, N., F. L. Cosset, and A. L. Epstein. 1997. Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors. J. Virol. 71:4111-4117.
57. Scadden, D. T., B. Fuller, and J. M. Cunningham. 1990. Human cells infected with retrovirus vectors acquire an endogenous murine provirus. J. Virol. 64:424-427.
58. Sena-Esteves, M., M. Aghi, P. A. Pechan, E. M. Kaye, and X. O. Breakefield. 1996. Gene delivery to the nervous system using retroviral vectors, p. 149-180. In D. S. Latchman (ed.), Genetic manipulation of the nervous system. Academic Press, London, England.
59. Smith, I. L., M. A. Hardwicke, and R. M. Sandri-Goldin. 1992. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 186:74-86.
60. Spaete, R. R., and N. Frenkel. 1982. The herpes simplex virus amplicon: analysis of cis-acting replication functions. Cell 30:295-304.
61. Takeuchi, Y., C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, F. L. Cosset, R. A. Weiss, and M. K. L. Collins. 1996. Sensitization of cells and retroviruses to human serum by alpha(1-3)galactosyltransferase. Nature 379: 85-88.
62. Tamiya, T., M. X. Wei, M. Chase, Y. Ono, F. Lee, X. O. Breakefield, and E. A. Chiocca. 1995. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producing cells. Gene Ther. 2:531-538.
63. Tamura, M., K. Shimizu, M. Yamada, Y. Miyao, T. Hayakawa, and K. Ikenaka. 1997. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum. Gene Ther. 8:381-391.
64. Wang, S., and J. M. Vos. 1996. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J. Virol. 70:8422-8430.
65. Weizsaecker, M., D. F. Deen, M. L. Rosenblum, T. Hoshino, P. H. Gutin, and M. Barker. 1981. The 9L rat brain tumor: description and application of an animal model. J. Neurol. 224:183-192.
66. Wendelburg, B. J., and J.-M. H. Vos. 1998. An enhanced EBNA-1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmid in human cells. Gene Ther. 5:1389-1399.
67. Yamada, M., K. Shimizu, Y. Miyao, T. Hayakawa, K. Nakajima, K. Nakahira, H. Nakagawa, K. Mikoshiba, and K. Ikenaka. 1994. Migration of genetically labeled glioma cells after implantation into murine brain. J. Neurosci. Res. 38:415-423.
68. Yates, J. L., N. Warren, and B. Sugden. 1985. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815.
69. Yoshida, Y., N. Emi, and H. Hamada. 1997. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem. Biophys. Res. Commun. 232:379-382.
70. Yoshii, Y., Y. Maki, K. Tsuboi, Y. Tomono, K. Nakagawa, and T. Hoshino. 1986. Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors. J. Neurosurg. 65:659-663.